Skip to main content
Clinical Trials/NCT06352320
NCT06352320
Recruiting
N/A

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH Trial): a National Multi-center, Retrospective-prospective, Cohort Study

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country500 target enrollmentMay 9, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiomyopathies
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
500
Locations
1
Primary Endpoint
Change in the incidence of mortality rate
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Detailed Description

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

Registry
clinicaltrials.gov
Start Date
May 9, 2024
End Date
August 31, 2032
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years old.
  • The diagnosis of cardiomyopathy was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion Criteria

  • Incomplete clinical data.
  • Do not agree to the inclusion or refuse to authorize the informed consent.

Outcomes

Primary Outcomes

Change in the incidence of mortality rate

Time Frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3, 5, 10 year.

The survival status will be obtained from the medical records and phone calls to patients or their family members

Study Sites (1)

Loading locations...

Similar Trials